Click here to close now.



Welcome!

News Feed Item

2013 US Hospital Cancer Diagnostics Market

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

2013 US Hospital Cancer Diagnostics Market

http://www.reportlinker.com/p01079355/2013-US-Hospital-Cancer-Diagnostics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

This new report from Venture Planning Group contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: 

  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals.  
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of  leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers. 

         Contains 567 pages and 50 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Brest Cancer

2. Lung Cancer

3. Colon and Rectum Cancer

4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

- ADA

- B-Protein

- PNP

- 5'-Nucleotidase

27. Oncogenes

- Abl/abl-bcr

- AIB1

- BCL-2

- BRCA1

- CD44

- C-fos

- C-myb

- C-myc

- CYP-17

- Erb-B

- HPC1

- N-myc

- P40

- P51

- P53

- PIK3CA

- PTI-1

- Ras

- Reg

- Sis

- Src

28. Polypeptide Growth Factors

- Basic Fibroblast Growth Factor

- Beta-TGF

- Cachectin (TNT)

- Calmodulin

- ECFR

- Nerve Growth Factor (NGF)

- Epidermal Growth Factor (EGF)

- Ornithine Decarboxylase

- Transferrin

- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon

- B Cell Growth Factors

- B Cell Growth Factor (BCGF)

- Gamma-Interferon

- Interleukin-1 (IL-1)

- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine

- Actin

- Alpha-Actin

- Antineuronal Antibodies

- 7B2

- B72.3

- Bax

- BCD-F9

- BLCA-4

- Blood Group Antigens A,B,H

- CA 50

- CA 72-4/TAG-72

- CA 195

- CA-242

- CA-549

- CAM 26

- CAR-3

- Cathepsin-D

- Chromogranin A and B

- Cluster 1 Antigen

- Cluster-5/5A Antigen

- CTA

- CU18

- DR-70

- DU-PAN-2

- Endometrial Bleeding Associated Factor

- Endostatin

- Epithelial Membrane Antigen

- Feulgen Hydrolysis

- Fibronectin

- FSH

- (1->3)-L-fucosyltransferase

- Gastrin-Releasing Peptide (GRP)

- GDCFP-15

- Glucagon

- Glycoamines

- H23

- Her-2

- Human Carcinoma Antigen

- HPA

- HSP27

- Intermediate Filaments

- Cytokeratins/CK18/Cyfra 21-1

- Desmin

- Gliofibrillary Acid Protein

- Neurofilaments

- Vimentin

- KA 93

- Kinases

- KP16D3

- LAI

- Leukocyte Common Antigen

- Lewis Antigens

- Lysophosphatidic Acid (LPA)

- Ma 695/Ma 552

- MABDF3

- MAG

- ME1

- Minactivin

- MN/CA9

- MSA

- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor 1

- Myosin

- NEA-130

- NMP22

- OA-519

- Opiod Peptides

- P-glycoprotein

- Pancreatic Oncofetal Antigen (POA)

- Placental Lactogen

- PR92

- Proliferative Index, Ki-67

- Px

- RB Inactivation/Deletion

- Ret

- SCCL 175

- Selectin

- Sialic Acid

- Sialyl SSEA-1/SLX

- SN10

- Somatostatin

- TA-90

- TABA

- Tachykinin

- TAG 12

- TPS

- Troponin

- Tubulin

- VCAM

- VEGF

- Villen

C. Instrumentation Review

And Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

- PCR

- DAP-PCR

- Immuno-PCR

- QC-PCR

- CAR

- DNA

- HPA

- LCR

- NASBA

- QBR

- SDA

- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Industry Consolidation

4. Managed Care

5. Hospitals

6. Admissions

7. Length of Stay

8. Industry Diversification

9. Physician Demographics

10. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

11. Laboratory Regulations

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Point-Of-Care Testing

d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Dako

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Otho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

List of Tables

Tumor Marker Classification

Major Companies Developing or Marketing

ACTH Tests

Major Companies Developing or Marketing

AFP Tests

Major Companies Developing or Marketing

Beta-2 Microglobulin Tests

Major Companies Developing or Marketing

CA 15-3/27.29 Tests

Major Companies Developing or Marketing

CA 19-9 Tests

Major Companies Developing or Marketing

CA 125 Tests

Major Companies Developing or Marketing

Calcitonin Tests

Major Companies Developing or Marketing

CEA Tests

Major Companies Developing or Marketing

Estrogen Receptor Tests

Major Companies Developing or Marketing

Progesterone Receptor Tests

Major Companies Developing or Marketing

Ferritin Tests

Major Companies Developing or Marketing

Gastrin Tests

Major Companies Developing or Marketing

HCG Tests

Major Companies Developing or Marketing

Insulin Tests

Major Companies Developing or Marketing

NSE Tests

Major Companies Developing or Marketing

Occult Blood Tests

Major Companies Developing or Marketing

PAP Smear/HPV Tests

Major Companies Developing or Marketing

PAP Tests

Major Companies Developing or Marketing

PSA Tests

Major Companies Developing or Marketing

Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications

In Cancer Diagnosis

Oncogenes Potential Applications

In Cancer Diagnosis

Major Companies Developing or Marketing

Oncogene Tests

Growth Factors Potential Applications

In Cancer Diagnosis

Colony Stimulating Factors Potential

Applications in Cancer Diagnosis

Lymphokines Potential Applications

In Cancer Diagnosis

Immunohistochemical Stains Potential

Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital

Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates

Per 100,000 Population

U.S., Laboratories Performing Cancer Diagnostic

Tests

U.S., Hospital Laboratories Performing

Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer

Diagnostic Test Volume Forecast by Test

U.S., Total Cancer Diagnostics Sales

By Major Supplier

U.S., ACTH Testing Market Diagnostics

Sales by Major Supplier

U.S., AFP Testing Market Diagnostics

Sales by Major Supplier

U.S., Beta-2 Migroblolulin Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 15-3/27.29 Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 19-9 Testing Market Diagnostics

Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics

Sales by Major Supplier

U.S., CEA Testing Market Diagnostics

Sales by Major Supplier

U.S., Ferritin Testing Market

Diagnostics Sales by Major Supplier

U.S., HCG Testing Market

Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market

Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing

Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics

Sales by Major Supplier

U.S., Progesterone Receptor Testing Market

Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics

Sales by Major Supplier

To order this report:

Diagnostics Industry: 2013 US Hospital Cancer Diagnostics Market

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
CIOs and those charged with running IT Operations are challenged to deliver secure, audited, and reliable compute environments for the applications and data for the business. Behind the scenes these tasks are often accomplished by following onerous time-consuming processes and often the management of these environments and processes will be outsourced to multiple IT service providers. In addition, the division of work is often siloed into traditional "towers" that are not well integrated for cro...
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
Sensors and effectors of IoT are solving problems in new ways, but small businesses have been slow to join the quantified world. They’ll need information from IoT using applications as varied as the businesses themselves. In his session at @ThingsExpo, Roger Meike, Distinguished Engineer, Director of Technology Innovation at Intuit, showed how IoT manufacturers can use open standards, public APIs and custom apps to enable the Quantified Small Business. He used a Raspberry Pi to connect sensors...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, will provide an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data profes...
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, will discuss using predictive analytics to ...
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Fortunately, meaningful and tangible business cases for IoT are plentiful in a broad array of industries and vertical markets. These range from simple warranty cost reduction for capital intensive assets, to minimizing downtime for vital business tools, to creating feedback loops improving product design, to improving and enhancing enterprise customer experiences. All of these business cases, which will be briefly explored in this session, hinge on cost effectively extracting relevant data from ...